Dr. Sepp holds a PhD in neuroscience from the University of British Columbia, Vancouver, and completed her postdoctoral work at Harvard Medical School as a fellow of the Canadian Institutes of Health Research (CIHR).  Her research has centered on the development of live-cell, high-content screening techniques in primary neurons for application to both genetic analysis and drug discovery.  The ultimate goals of her work are to accelerate the process of early stage drug discovery for neurodegenerative disorders, and identify disease-modifying therapeutics that can halt or reverse the course of neuronal degeneration.  Stemming from a fruitful scientific collaboration on a polyglutamine neurodegeneration drug discovery model with Dr. Joost Schulte at the Massachusetts Institute of Technology (MIT), she and Dr. Schulte co-founded Oxalys Pharmaceuticals.  Dr. Sepp is currently focused on development of new drug discovery platforms for Parkinson’s disease, and on preclinical validation of Parkinson’s disease treatments.